A Combination Treatment Reduces Acne Severity and PIHP

A Combination of a Dermocosmetic and a Tainted Sunscreen Reduce Acne Severity and Signs of Post-inflammatory Hyperpigmentation in Subjects With a Fitzpatrick Phototype Ranging From IV to VI

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05601960

Enrollment

1785

Registered

2022-11-01

Start date

2020-04-15

Completion date

2021-02-28

Last updated

2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne, Postinflammatory Hyperpigmentation

Brief summary

Acne is a chronic, inflammatory skin condition. It may cause scars and post-inflammatory hyperpigmentation (PIHP). PIHP frequently affects individuals with a phototype of IV or above.\[1\] PIHP is worsened by UV radiation, lasts for years and impacts the individual well-being.\[2, 3\] In an observational study, 1785 adults with a phototype ranging from IV to VI with acne and PIHP applied daily for 2 months a dermocosmetic and a tainted sunscreen product (DC, Effaclar® Duo (+); SS, Anthelios® Shaka Fluide SPF 50+, SS; both La Roche-Posay Laboratoire Dermatologique, France.

Interventions

OTHERanti-acne dermocosmetic

Topical application once daily for 2 months

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* adult * mild to moderate acne * presence of postinflammatory hyperpigmentation lesions * phototype IV to VI

Exclusion criteria

* less than 18 years * severe acne

Design outcomes

Primary

Measure	Time frame	Description
non-inflammatory lesions	baseline	lesion count
seborrhoea level	baseline	visual analog scale scale 0=none to 10= very severe
acne severity	baseline	GEA (Global evaluation of acne) scale 0=none to 5=very severe
PAHPI: post-acne hyperpigmentation index	baseline	post-acne hyperpigmentation index from \<3mm to \>10mm
inflammatory lesions	baseline	lesion count

Secondary

Measure	Time frame	Description
Investigator satisfaction acne	Month 2	visual analog scale from very unsatified=0 to very satisfied=5
Investigator satisfaction	Month 2	visual analog scale from very unsatified=0 to very satisfied=5
Patient satisfaction acne	Month 2	visual analog scale from very unsatified=0 to very satisfied=5
Patient satisfaction PAHPI	Month 2	visual analog scale from very unsatified=0 to very satisfied=5
Patient: Skin quality	Month 2	visual analog scale from very unsatified=0 to very satisfied=5

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026